LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Mirzabeigi, Parastoo"
  2. AU="Lesage, C"
  3. AU=Kim Donghyun AU=Kim Donghyun
  4. AU="Weisburd, Ben"
  5. AU="van den Berg, Linda M"
  6. AU="Kurochkina, Yu D"
  7. AU="H Cao"
  8. AU="Elias, Rui"
  9. AU="Hofstaedter, Ferdinand"
  10. AU="Ross, Ashley E"
  11. AU="Luque Alarcón, Mónica"

Suchergebnis

Treffer 1 - 8 von insgesamt 8

Suchoptionen

  1. Artikel ; Online: A Review of Therapeutic Antibodies in Breast Cancer.

    Eini, Maryam / Zainodini, Nahid / Montazeri, Hamed / Mirzabeigi, Parastoo / Tarighi, Parastoo

    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques

    2021  Band 24, Seite(n) 363–380

    Abstract: Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer. By developing different types of monoclonal antibodies such as humanized, drug ... ...

    Abstract Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer. By developing different types of monoclonal antibodies such as humanized, drug conjugated, or bispecific ones, researchers, have achieved remarkable success in treating several complicated and challenging diseases, targeting specific antigens or receptors makes monoclonal antibodies the right choice to inhibit signaling pathways like programmed death-ligand 1 (PD-L1) or programmed death1 (PD-1) and changing cell behavior. As one of the most common types of malignancies among women, breast cancer is one of the most critical conditions which different types of monoclonal antibodies were designed and produced to treat. Therefore, we reviewed these antibodies in breast cancer, their targets, and their efficacy and toxicity, with more focus on recent PD-L1or PD-1 inhibitor antibodies in breast cancer and beyond.
    Mesh-Begriff(e) Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacology ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/pharmacology ; B7-H1 Antigen/immunology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/immunology ; Female ; Humans ; Programmed Cell Death 1 Receptor/immunology
    Chemische Substanzen Antibodies, Monoclonal ; Antineoplastic Agents, Immunological ; B7-H1 Antigen ; CD274 protein, human ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor
    Sprache Englisch
    Erscheinungsdatum 2021-07-23
    Erscheinungsland Canada
    Dokumenttyp Journal Article ; Review
    ZDB-ID 1422972-9
    ISSN 1482-1826 ; 1482-1826
    ISSN (online) 1482-1826
    ISSN 1482-1826
    DOI 10.18433/jpps31864
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: In-vitro

    Sabernavaei, Mahsa / Montazeri, Hamed / Mirzabeigi, Parastoo / Sharafi-Badr, Paria / Zamani, Mozhdeh / Hadjiakhoondi, Abbas / Yassaa, Narguess / Kobarfard, Farzad

    Natural product research

    2023  , Seite(n) 1–8

    Abstract: Medicinal plants such ... ...

    Abstract Medicinal plants such as
    Sprache Englisch
    Erscheinungsdatum 2023-10-27
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2185747-7
    ISSN 1478-6427 ; 1478-6419
    ISSN (online) 1478-6427
    ISSN 1478-6419
    DOI 10.1080/14786419.2023.2275286
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Anti-Acinetobacter Baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model.

    Basardeh, Eilnaz / Piri-Gavgani, Somayeh / Moradi, Hamid Reza / Azizi, Masoumeh / Mirzabeigi, Parastoo / Nazari, Farzaneh / Ghanei, Mostafa / Mahboudi, Fereidoun / Rahimi-Jamnani, Fatemeh

    BMC microbiology

    2024  Band 24, Heft 1, Seite(n) 55

    Abstract: Background: The emergence of carbapenem-resistant and extensively drug-resistant (XDR) Acinetobacter baumannii as well as inadequate effective antibiotics calls for an urgent effort to find new antibacterial agents. The therapeutic efficacy of two human ...

    Abstract Background: The emergence of carbapenem-resistant and extensively drug-resistant (XDR) Acinetobacter baumannii as well as inadequate effective antibiotics calls for an urgent effort to find new antibacterial agents. The therapeutic efficacy of two human scFvs, EB211 and EB279, showing growth inhibitory activity against A. baumannii in vitro, was investigated in immunocompromised mice with A. baumannii pneumonia.
    Results: The data revealed that infected mice treated with EB211, EB279, and a combination of the two scFvs showed better survival, reduced bacterial load in the lungs, and no marked pathological abnormalities in the kidneys, liver, and lungs when compared to the control groups receiving normal saline or an irrelevant scFv.
    Conclusions: The results from this study suggest that the scFvs with direct growth inhibitory activity could offer promising results in the treatment of pneumonia caused by XDR A. baumannii.
    Mesh-Begriff(e) Humans ; Animals ; Mice ; Acinetobacter baumannii ; Single-Chain Antibodies/pharmacology ; Single-Chain Antibodies/therapeutic use ; Acinetobacter Infections/drug therapy ; Acinetobacter Infections/microbiology ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Pneumonia/drug therapy ; Pneumonia/microbiology ; Drug Resistance, Multiple, Bacterial ; Microbial Sensitivity Tests
    Chemische Substanzen Single-Chain Antibodies ; Anti-Bacterial Agents
    Sprache Englisch
    Erscheinungsdatum 2024-02-10
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2041505-9
    ISSN 1471-2180 ; 1471-2180
    ISSN (online) 1471-2180
    ISSN 1471-2180
    DOI 10.1186/s12866-023-03080-9
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

    Janani, Leila / Bamehr, Hadi / Tanha, Kiarash / Mirzabeigi, Parastoo / Montazeri, Hamed / Tarighi, Parastoo

    Drug research

    2021  Band 71, Heft 9, Seite(n) 477–488

    Abstract: Background: Sitagliptin is known as an antidiabetic agent inhibiting the dipeptidyl peptidase-4. Although sitagliptin may influence weight, controversial results have been reported, and there is no general agreement on this issue. Therefore, this study ... ...

    Abstract Background: Sitagliptin is known as an antidiabetic agent inhibiting the dipeptidyl peptidase-4. Although sitagliptin may influence weight, controversial results have been reported, and there is no general agreement on this issue. Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes.
    Methods: We reviewed the following databases to identify all relevant papers published until 1st April 2021: Web of Science, MEDLINE, Embase, Scopus, Cochrane Central Register of Controlled Trials Cochrane Library, and Google Scholar. The research included all clinical trials investigating the effect of sitagliptin in obese or overweight adult patients with type 2 diabetes without any language restriction.
    Results: In total, eighteen randomized controlled trials with 2009 participants were included in our meta-analysis. Results showed supplementation of sitagliptin has led to weight loss for sitagliptin treated (MD  -0.99; 95% CI; (-1.87, -0.12); p=0.026)) and sitagliptin+metformin treated groups (MD  -1.09; 95% CI; (-1.69, -0.49); p<0.001)). Also, the intervention has influenced body mass index in sitagliptin treated (MD  -0.23; 95% CI; (-0.45, 0.02); p=0.033)) and sitagliptin+metformin treated groups (MD -0.52; 95% CI; (-0.96, 0.08); p=0.020)) comparing to placebo.
    Conclusion: Our results demonstrated that sitagliptin administration with or without metformin might reduce the body weight and body mass index if these drugs are taken for more than 6 months.
    Mesh-Begriff(e) Adult ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Drug Therapy, Combination ; Glycated Hemoglobin A ; Humans ; Hypoglycemic Agents/therapeutic use ; Metformin/therapeutic use ; Obesity/complications ; Obesity/drug therapy ; Overweight/complications ; Overweight/drug therapy ; Randomized Controlled Trials as Topic ; Sitagliptin Phosphate/therapeutic use ; Weight Loss
    Chemische Substanzen Glycated Hemoglobin A ; Hypoglycemic Agents ; Metformin (9100L32L2N) ; Sitagliptin Phosphate (TS63EW8X6F)
    Sprache Englisch
    Erscheinungsdatum 2021-08-13
    Erscheinungsland Germany
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2703847-6
    ISSN 2194-9387 ; 2194-9379
    ISSN (online) 2194-9387
    ISSN 2194-9379
    DOI 10.1055/a-1555-2797
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uf I Zs.151: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.

    Tarighi, Parastoo / Eftekhari, Samane / Chizari, Milad / Sabernavaei, Mahsa / Jafari, Davod / Mirzabeigi, Parastoo

    European journal of pharmacology

    2021  Band 895, Seite(n) 173890

    Abstract: The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high prevalence and easy transmission, which is expanding globally with no conventional treatment or vaccine. The new virus revealed 79% and 50% genomic similarities with severe ...

    Abstract The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high prevalence and easy transmission, which is expanding globally with no conventional treatment or vaccine. The new virus revealed 79% and 50% genomic similarities with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), respectively. Accordingly, since the disease resists testing and adopting new therapeutics, repositioning pre-existing drugs may present a fast and attractive strategy with known safety, characteristics, and dosage used. However, they are not specific and targeted. Therefore, several drugs have been investigated for their efficacy and safety in the treatment of COVID-19; most of them are undergoing clinical trials. This article summarizes clinical investigations of potential therapeutic drugs used as COVID-19 therapy. Subsequently, it prepares a pattern of results and therapeutic targets to help further experiment designs. We have investigated drugs as classified in the following three groups; 1) The drugs which computationally showed effectiveness (in silico) but needed further lab confirmations; 2) Emetine, Teicoplanin, and Nelfinavir have shown effectiveness in vitro; 3) The drugs currently under clinical trial.
    Mesh-Begriff(e) Animals ; Antiviral Agents/therapeutic use ; COVID-19/virology ; Humans ; Pandemics/prevention & control ; SARS-CoV-2/drug effects ; COVID-19 Drug Treatment
    Chemische Substanzen Antiviral Agents
    Sprache Englisch
    Erscheinungsdatum 2021-01-20
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Review
    ZDB-ID 80121-5
    ISSN 1879-0712 ; 0014-2999
    ISSN (online) 1879-0712
    ISSN 0014-2999
    DOI 10.1016/j.ejphar.2021.173890
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 522: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel: [Titelangabe fehlt]

    Janani, Leila / Bamehr, Hadi / Tanha, Kiarash / Mirzabeigi, Parastoo / Montazeri, Hamed / Tarighi, Parastoo

    Drug Research

    2021  Band 71, Heft 09, Seite(n) 477–488

    Abstract: Background: Sitagliptin is known as an antidiabetic agent inhibiting the dipeptidyl peptidase-4. Although sitagliptin may influence weight, controversial results have been reported, and there is no general ... ...

    Abstract Background: Sitagliptin is known as an antidiabetic agent inhibiting the dipeptidyl peptidase-4. Although sitagliptin may influence weight, controversial results have been reported, and there is no general agreement on this issue. Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes.
    Methods: We reviewed the following databases to identify all relevant papers published until 1st April 2021: Web of Science, MEDLINE, Embase, Scopus, Cochrane Central Register of Controlled Trials Cochrane Library, and Google Scholar. The research included all clinical trials investigating the effect of sitagliptin in obese or overweight adult patients with type 2 diabetes without any language restriction.
    Results: In total, eighteen randomized controlled trials with 2009 participants were included in our meta-analysis. Results showed supplementation of sitagliptin has led to weight loss for sitagliptin treated (MD  −0.99; 95% CI; (−1.87, −0.12); p=0.026)) and sitagliptin+metformin treated groups (MD  −1.09; 95% CI; (−1.69, −0.49); p<0.001)). Also, the intervention has influenced body mass index in sitagliptin treated (MD  −0.23; 95% CI; (−0.45, 0.02); p=0.033)) and sitagliptin+metformin treated groups (MD −0.52; 95% CI; (−0.96, 0.08); p=0.020)) comparing to placebo.
    Conclusion: Our results demonstrated that sitagliptin administration with or without metformin might reduce the body weight and body mass index if these drugs are taken for more than 6 months.
    Schlagwörter Systematic review ; Meta-analysis ; Randomised clinical trial ; Type 2 diabetes ; Sitagliptin ; Overweight ; Metformin
    Sprache Englisch
    Erscheinungsdatum 2021-08-13
    Verlag Georg Thieme Verlag KG
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 2703847-6
    ISSN 2194-9387 ; 2194-9379
    ISSN (online) 2194-9387
    ISSN 2194-9379
    DOI 10.1055/a-1555-2797
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uf I Zs.151: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Evaluation of clinical pharmacist's interventions in an infectious diseases ward and impact on patient's direct medication cost.

    Khalili, Hossein / Karimzadeh, Iman / Mirzabeigi, Parastoo / Dashti-Khavidaki, Simin

    European journal of internal medicine

    2013  Band 24, Heft 3, Seite(n) 227–233

    Abstract: Background: A clinical pharmacist is a key member of the antimicrobial multidisciplinary team involved in patients' pharmacotherapy monitoring. The aim of this study was to determine the frequency and type of medication errors, the type of clinical ... ...

    Abstract Background: A clinical pharmacist is a key member of the antimicrobial multidisciplinary team involved in patients' pharmacotherapy monitoring. The aim of this study was to determine the frequency and type of medication errors, the type of clinical pharmacy interventions, acceptance of pharmacist interventions by health-care provider team, nursing staff satisfaction with clinical pharmacy services, and the probable impact of clinical pharmacy interventions on decreasing direct medication costs at an infectious diseases ward in Iran.
    Methods: All clinical pharmacist interventions such as preventing medication errors were recorded in a previously designed pharmacotherapy monitoring forms. Direct medication cost of patients admitted during the study period was compared with that of subjects hospitalized at the same ward during the year before the intervention period to determine the impact of clinical pharmacy interventions on direct medication costs.
    Results: The 3 most frequent medication error types were incorrect dose (35.5%), omission error (24.3%), and incorrect medication (14.3%). The mean number of clinical pharmacist intervention per patient was 3.2. Forty percent of clinical pharmacists' interventions are moderate to major clinical significant. Thirty nine percent of clinical pharmacist's interventions had moderate to major financial benefits in present study. The direct medication cost per patient was decreased about 3.8% following clinical pharmacist's interventions.
    Conclusion: Our data demonstrated that incorrect dose was the most frequent medication error in the infectious diseases ward. Major portion of clinical pharmacist interventions were accepted by physicians and nursing staff. Clinical pharmacist interventions non-significantly decreased the direct medication cost of patients.
    Mesh-Begriff(e) Adult ; Aged ; Communicable Diseases/classification ; Communicable Diseases/drug therapy ; Communicable Diseases/economics ; Drug Costs ; Drug Monitoring/methods ; Economics, Hospital/statistics & numerical data ; Female ; Humans ; Iran ; Male ; Medication Errors/classification ; Medication Errors/prevention & control ; Medication Errors/statistics & numerical data ; Middle Aged ; Organizational Case Studies ; Patient Care Team/organization & administration ; Pharmacists/economics ; Pharmacists/standards ; Pharmacy Service, Hospital/economics ; Pharmacy Service, Hospital/methods ; Practice Patterns, Physicians'/economics ; Practice Patterns, Physicians'/statistics & numerical data ; Professional Role ; Prospective Studies
    Sprache Englisch
    Erscheinungsdatum 2013-04
    Erscheinungsland Netherlands
    Dokumenttyp Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2012.11.014
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2608: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel: The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial.

    Mirzabeigi, Parastoo / Mohammadpour, Amir Hooshang / Salarifar, Mojtaba / Gholami, Kheirollah / Mojtahedzadeh, Mojtaba / Javadi, Mohammad Reza

    Iranian journal of pharmaceutical research : IJPR

    2015  Band 14, Heft 2, Seite(n) 479–486

    Abstract: Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovascular risk factors ... ...

    Abstract Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovascular risk factors in patients with coronary artery disease (CAD). A total of 33 patients with CAD who fulfilled inclusion and exclusion criteria were entered the study. Patients were randomly assigned to receive curcumin or placebo, 500 mg capsules, four times daily for 8 weeks. Lipid profile, blood glucose and high sensitive C-reactive protein (hs-CRP) levels were analyzed at baseline and two months after treatment. Serum levels of triglycerides (P=0.01), LDL-cholesterol (P=0.03) and VLDL-cholesterol (P=0.04) significantly decreased in the curcumin group compared to baseline, without significant changes in total cholesterol, HDL-cholesterol, blood glucose and hs-CRP levels. In all mentioned laboratory parameters, significant difference was not detected between curcumin and placebo. Although curcumin improved some of lipid profile components, it did not show appreciable effect on inflammatory markers in patients with CAD. Therefore, more detailed assessment of metabolic effects or anti-inflammatory activities of curcumin need to perform by extensive human study.
    Sprache Englisch
    Erscheinungsdatum 2015-04-15
    Erscheinungsland Iran
    Dokumenttyp Journal Article
    ZDB-ID 2578271-X
    ISSN 1726-6890 ; 1735-0328 ; 1735-0328
    ISSN (online) 1726-6890 ; 1735-0328
    ISSN 1735-0328
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang